RE:RE:eyes on the prizeThat's exactly what Big Pharma wants to do, since having full control over a Phase 3's trial design and implementation, further allows for selection of trial sites, timely patient enrollment, efficient trial data collection, and relatively unrestricted communications with the FDA which ultimately provides for the quicker filing of a BLA, review and the issuance of a potential accelerated approval, which would happen well in advance of the trial's final readout. In so doing, Big Pharma is better able to develop it's regulatory, manufacturing, distribution, and marketing & sales plans, while the Phase 3 trial is ocurring and in anticipation of the FDA's 'Accelerated' Approvable Letter.
Big Pharma's full control of a Phase 3 trial saves BP both time and money.